Predictive Health Intelligence
@predictivehealth.bsky.social
Ending the late diagnosis of liver disease.
ICYMI: RCHT has begun using hepatoSIGHT® to help find people at risk of liver disease earlier.
As Liz Farrington, Consultant Nurse in Hepatology at RCHT, said, earlier identification can “genuinely change lives.”
BBC coverage: www.bbc.co.uk/news/article...
As Liz Farrington, Consultant Nurse in Hepatology at RCHT, said, earlier identification can “genuinely change lives.”
BBC coverage: www.bbc.co.uk/news/article...
New system supports earlier diagnosis of liver disease
Royal Cornwall Hospital NHS says the new digital tool supports preventative care.
www.bbc.co.uk
May 20, 2026 at 12:34 PM
ICYMI: RCHT has begun using hepatoSIGHT® to help find people at risk of liver disease earlier.
As Liz Farrington, Consultant Nurse in Hepatology at RCHT, said, earlier identification can “genuinely change lives.”
BBC coverage: www.bbc.co.uk/news/article...
As Liz Farrington, Consultant Nurse in Hepatology at RCHT, said, earlier identification can “genuinely change lives.”
BBC coverage: www.bbc.co.uk/news/article...
Dr's @timjobson.bsky.social and Katie Denver will attend the Global Think-tank on Steatotic Liver Disease in Barcelona this month.
We look forward to contributing to discussions on ways to improve early detection, prevention, and access to care for people with #liverdisease
#SLDThinkTank
We look forward to contributing to discussions on ways to improve early detection, prevention, and access to care for people with #liverdisease
#SLDThinkTank
May 13, 2026 at 12:28 PM
Dr's @timjobson.bsky.social and Katie Denver will attend the Global Think-tank on Steatotic Liver Disease in Barcelona this month.
We look forward to contributing to discussions on ways to improve early detection, prevention, and access to care for people with #liverdisease
#SLDThinkTank
We look forward to contributing to discussions on ways to improve early detection, prevention, and access to care for people with #liverdisease
#SLDThinkTank
Great news for people in Cornwall.
Royal Cornwall Hospitals NHS Trust is now using hepatoSIGHT® to help proactively find people at risk of liver disease, using historic blood test data already held within NHS systems.
A positive shift toward preventive care in the South West.
🔗 lnkd.in/eVuZmUCE
Royal Cornwall Hospitals NHS Trust is now using hepatoSIGHT® to help proactively find people at risk of liver disease, using historic blood test data already held within NHS systems.
A positive shift toward preventive care in the South West.
🔗 lnkd.in/eVuZmUCE
May 12, 2026 at 8:19 AM
Great news for people in Cornwall.
Royal Cornwall Hospitals NHS Trust is now using hepatoSIGHT® to help proactively find people at risk of liver disease, using historic blood test data already held within NHS systems.
A positive shift toward preventive care in the South West.
🔗 lnkd.in/eVuZmUCE
Royal Cornwall Hospitals NHS Trust is now using hepatoSIGHT® to help proactively find people at risk of liver disease, using historic blood test data already held within NHS systems.
A positive shift toward preventive care in the South West.
🔗 lnkd.in/eVuZmUCE
#Liverdisease is one of the clearest examples of #healthinequality in the UK.
Our latest “In Practice with Dr Denver” explores deprivation, late diagnosis, and whether #NHS biomarker-driven case-finding could support #earlieridentification.
Read it here:
www.linkedin.com/pulse/liver-...
Our latest “In Practice with Dr Denver” explores deprivation, late diagnosis, and whether #NHS biomarker-driven case-finding could support #earlieridentification.
Read it here:
www.linkedin.com/pulse/liver-...
Liver Disease, Deprivation & Late Diagnosis.
Introduction Liver disease is one of the clearest examples of health inequality within the UK. Unlike many other major diseases, liver-related mortality continues to rise, with the burden falling disp...
www.linkedin.com
May 6, 2026 at 10:39 AM
#Liverdisease is one of the clearest examples of #healthinequality in the UK.
Our latest “In Practice with Dr Denver” explores deprivation, late diagnosis, and whether #NHS biomarker-driven case-finding could support #earlieridentification.
Read it here:
www.linkedin.com/pulse/liver-...
Our latest “In Practice with Dr Denver” explores deprivation, late diagnosis, and whether #NHS biomarker-driven case-finding could support #earlieridentification.
Read it here:
www.linkedin.com/pulse/liver-...
Proud to sponsor A3UK with Global Liver Institute. Thank you to everyone involved, especially the patients.
Living with a condition is hard, choosing to advocate for others as well is inspiring.
Special thanks to our patient rep, Peter Ernest for his continued support.
#liverdisease #publichealth
Living with a condition is hard, choosing to advocate for others as well is inspiring.
Special thanks to our patient rep, Peter Ernest for his continued support.
#liverdisease #publichealth
April 13, 2026 at 10:23 AM
Proud to sponsor A3UK with Global Liver Institute. Thank you to everyone involved, especially the patients.
Living with a condition is hard, choosing to advocate for others as well is inspiring.
Special thanks to our patient rep, Peter Ernest for his continued support.
#liverdisease #publichealth
Living with a condition is hard, choosing to advocate for others as well is inspiring.
Special thanks to our patient rep, Peter Ernest for his continued support.
#liverdisease #publichealth
Announcing: 996 participants recruited from a single NHS site in under a year!
The LiveWell study shows how hepatoSIGHT®, genetics, and decentralised delivery can improve recruitment for #NHS sites and sponsors.
👀 predictivehealthintelligence.co.uk/news/precisi...
Full results later this year.
The LiveWell study shows how hepatoSIGHT®, genetics, and decentralised delivery can improve recruitment for #NHS sites and sponsors.
👀 predictivehealthintelligence.co.uk/news/precisi...
Full results later this year.
March 18, 2026 at 10:17 AM
Announcing: 996 participants recruited from a single NHS site in under a year!
The LiveWell study shows how hepatoSIGHT®, genetics, and decentralised delivery can improve recruitment for #NHS sites and sponsors.
👀 predictivehealthintelligence.co.uk/news/precisi...
Full results later this year.
The LiveWell study shows how hepatoSIGHT®, genetics, and decentralised delivery can improve recruitment for #NHS sites and sponsors.
👀 predictivehealthintelligence.co.uk/news/precisi...
Full results later this year.
Join our Managing Director Neil Stevens @ the Creative Disruption Forum in London, 19 March
His keynote, “Harnessing NHS data for research and preventative care”, will explore how better trial design and recruitment can strengthen UK research and improve patient outcomes.
Tickets: lnkd.in/eepXqatZ
His keynote, “Harnessing NHS data for research and preventative care”, will explore how better trial design and recruitment can strengthen UK research and improve patient outcomes.
Tickets: lnkd.in/eepXqatZ
March 12, 2026 at 10:46 AM
Join our Managing Director Neil Stevens @ the Creative Disruption Forum in London, 19 March
His keynote, “Harnessing NHS data for research and preventative care”, will explore how better trial design and recruitment can strengthen UK research and improve patient outcomes.
Tickets: lnkd.in/eepXqatZ
His keynote, “Harnessing NHS data for research and preventative care”, will explore how better trial design and recruitment can strengthen UK research and improve patient outcomes.
Tickets: lnkd.in/eepXqatZ
Co-existing #T2DM + #MASLD is a cardiovascular high-risk phenotype, and often missed until too late.
~2x higher #MACE risk vs T2DM alone, even beyond traditional risk factors.
Katie Denver breaks down why and what it means for earlier identification.
Read: www.linkedin.com/posts/predic...
~2x higher #MACE risk vs T2DM alone, even beyond traditional risk factors.
Katie Denver breaks down why and what it means for earlier identification.
Read: www.linkedin.com/posts/predic...
Co-existing T2DM and MASLD: A cardiovascular high-risk phenotype. | Predictive Health Intelligence
In Practice with Dr Denver: Co-existing T2DM and MASLD: A cardiovascular high-risk phenotype.
Public health systems are facing a tsunami of metabolic disease, and the downstream impact is stark.
Car...
www.linkedin.com
February 19, 2026 at 10:16 AM
Co-existing #T2DM + #MASLD is a cardiovascular high-risk phenotype, and often missed until too late.
~2x higher #MACE risk vs T2DM alone, even beyond traditional risk factors.
Katie Denver breaks down why and what it means for earlier identification.
Read: www.linkedin.com/posts/predic...
~2x higher #MACE risk vs T2DM alone, even beyond traditional risk factors.
Katie Denver breaks down why and what it means for earlier identification.
Read: www.linkedin.com/posts/predic...
Wishing our collaborators in the Middle East, and everyone observing Ramadan, a peaceful month ahead.
#RamadanMubarak
#RamadanMubarak
February 17, 2026 at 1:36 PM
Wishing our collaborators in the Middle East, and everyone observing Ramadan, a peaceful month ahead.
#RamadanMubarak
#RamadanMubarak
The #NHS #CancerPlan puts earlier diagnosis and prevention front and centre. For #livercancer: 6,600 UK cases/yr, stage 1 survival x4 higher than stage 4.
hepatoSIGHT helps teams find high-risk cases earlier using historic blood tests, without a major IT lift:
🔗 predictivehealthintelligence.co.uk
hepatoSIGHT helps teams find high-risk cases earlier using historic blood tests, without a major IT lift:
🔗 predictivehealthintelligence.co.uk
February 5, 2026 at 1:37 PM
The #NHS #CancerPlan puts earlier diagnosis and prevention front and centre. For #livercancer: 6,600 UK cases/yr, stage 1 survival x4 higher than stage 4.
hepatoSIGHT helps teams find high-risk cases earlier using historic blood tests, without a major IT lift:
🔗 predictivehealthintelligence.co.uk
hepatoSIGHT helps teams find high-risk cases earlier using historic blood tests, without a major IT lift:
🔗 predictivehealthintelligence.co.uk
New In Practice with Dr Denver.
Educational content for healthcare providers, not medical advice.
This article explores #PNPLA3 and what genetic risk means for stratifying and managing #MASLD in real-world #LiverDisease practice.
www.linkedin.com/pulse/pnpla3...
Educational content for healthcare providers, not medical advice.
This article explores #PNPLA3 and what genetic risk means for stratifying and managing #MASLD in real-world #LiverDisease practice.
www.linkedin.com/pulse/pnpla3...
PNPLA3 – Unlocking the potential for precision hepatology in MASLD.
Metabolic dysfunction-associated steatotic liver disease should not be thought of as a niche hepatology problem. It is increasingly encountered across primary care, diabetes services, cardiology, endo...
www.linkedin.com
January 15, 2026 at 1:21 PM
New In Practice with Dr Denver.
Educational content for healthcare providers, not medical advice.
This article explores #PNPLA3 and what genetic risk means for stratifying and managing #MASLD in real-world #LiverDisease practice.
www.linkedin.com/pulse/pnpla3...
Educational content for healthcare providers, not medical advice.
This article explores #PNPLA3 and what genetic risk means for stratifying and managing #MASLD in real-world #LiverDisease practice.
www.linkedin.com/pulse/pnpla3...
It’s no exaggeration to claim Dr @timjobson.bsky.social’s work could help many thousands live longer.
That's the headline of today's Somerset Gazette article on hepatoSIGHT®'s impact on #publichealth in the region.
🔗 www.somersetcountygazette.co.uk/news/2574050...
#liverdisease #NHS #NHSEngland
That's the headline of today's Somerset Gazette article on hepatoSIGHT®'s impact on #publichealth in the region.
🔗 www.somersetcountygazette.co.uk/news/2574050...
#liverdisease #NHS #NHSEngland
Interview: Meet the Somerset consultant helping save lives
Musgrove Park Hospital’s Dr Tim Jobson pioneers a new NHS data system in Somerset to detect early liver disease, improving UK patient outcomes and…
www.somersetcountygazette.co.uk
January 8, 2026 at 12:15 PM
It’s no exaggeration to claim Dr @timjobson.bsky.social’s work could help many thousands live longer.
That's the headline of today's Somerset Gazette article on hepatoSIGHT®'s impact on #publichealth in the region.
🔗 www.somersetcountygazette.co.uk/news/2574050...
#liverdisease #NHS #NHSEngland
That's the headline of today's Somerset Gazette article on hepatoSIGHT®'s impact on #publichealth in the region.
🔗 www.somersetcountygazette.co.uk/news/2574050...
#liverdisease #NHS #NHSEngland
A great morning yesterday at Nursing Live UK, where Dr Katie Denver shared how hepatoSIGHT® helps NHS teams spot liver disease risk earlier using existing blood test data.
Thanks to everyone who joined the discussion on early diagnosis and population health.
#NursingLive2025 #LiverHealth
Thanks to everyone who joined the discussion on early diagnosis and population health.
#NursingLive2025 #LiverHealth
November 6, 2025 at 5:45 PM
A great morning yesterday at Nursing Live UK, where Dr Katie Denver shared how hepatoSIGHT® helps NHS teams spot liver disease risk earlier using existing blood test data.
Thanks to everyone who joined the discussion on early diagnosis and population health.
#NursingLive2025 #LiverHealth
Thanks to everyone who joined the discussion on early diagnosis and population health.
#NursingLive2025 #LiverHealth
Dr Rebecca Cooper MP led a Westminster Hall debate on obesity and fatty liver disease, calling for early detection and treatment across England.
Proud that hepatoSIGHT® was highlighted as proof that clinical and digital teams can unite for patients.
#LiverDisease #NHS #MASLD
Proud that hepatoSIGHT® was highlighted as proof that clinical and digital teams can unite for patients.
#LiverDisease #NHS #MASLD
October 30, 2025 at 10:20 AM
Dr Rebecca Cooper MP led a Westminster Hall debate on obesity and fatty liver disease, calling for early detection and treatment across England.
Proud that hepatoSIGHT® was highlighted as proof that clinical and digital teams can unite for patients.
#LiverDisease #NHS #MASLD
Proud that hepatoSIGHT® was highlighted as proof that clinical and digital teams can unite for patients.
#LiverDisease #NHS #MASLD
Dr Katie Denver will be speaking at #NursingLive next month, sharing how hepatoSIGHT™ helps spot patients at risk of #liverdisease earlier using historic blood test results.
Enabling early identification and research in liver disease
10:00–10:45, Wed 5 Nov
Cardiometabolic zone, NEC
Enabling early identification and research in liver disease
10:00–10:45, Wed 5 Nov
Cardiometabolic zone, NEC
October 22, 2025 at 8:42 AM
Dr Katie Denver will be speaking at #NursingLive next month, sharing how hepatoSIGHT™ helps spot patients at risk of #liverdisease earlier using historic blood test results.
Enabling early identification and research in liver disease
10:00–10:45, Wed 5 Nov
Cardiometabolic zone, NEC
Enabling early identification and research in liver disease
10:00–10:45, Wed 5 Nov
Cardiometabolic zone, NEC
How can data help anticipate population needs?
Most #liverdisease is found late, when symptoms appear and the window for intervention is closing.
The #NHS already holds data that can predict risk. Case-finding helps clinicians identify patients sooner and enable earlier care.
👉 lnkd.in/eSMDDMPu
Most #liverdisease is found late, when symptoms appear and the window for intervention is closing.
The #NHS already holds data that can predict risk. Case-finding helps clinicians identify patients sooner and enable earlier care.
👉 lnkd.in/eSMDDMPu
October 15, 2025 at 10:29 AM
How can data help anticipate population needs?
Most #liverdisease is found late, when symptoms appear and the window for intervention is closing.
The #NHS already holds data that can predict risk. Case-finding helps clinicians identify patients sooner and enable earlier care.
👉 lnkd.in/eSMDDMPu
Most #liverdisease is found late, when symptoms appear and the window for intervention is closing.
The #NHS already holds data that can predict risk. Case-finding helps clinicians identify patients sooner and enable earlier care.
👉 lnkd.in/eSMDDMPu
Our collaborators at Somerset NHS FT & University Hospitals Bristol and Weston NHS FT will be presenting new data at #TheLiverMeeting #TLM25.
Exploring placebo response in #GLP-1 metabolic #liverdisease trials, crucial in understanding how trial results translate to the real world.
📍 Poster #4031
Exploring placebo response in #GLP-1 metabolic #liverdisease trials, crucial in understanding how trial results translate to the real world.
📍 Poster #4031
October 7, 2025 at 1:35 PM
Our collaborators at Somerset NHS FT & University Hospitals Bristol and Weston NHS FT will be presenting new data at #TheLiverMeeting #TLM25.
Exploring placebo response in #GLP-1 metabolic #liverdisease trials, crucial in understanding how trial results translate to the real world.
📍 Poster #4031
Exploring placebo response in #GLP-1 metabolic #liverdisease trials, crucial in understanding how trial results translate to the real world.
📍 Poster #4031
October is #LiverCancerAwarenessMonth.
DYK: In the 🇬🇧 #liver #cancer has surged with over 6k new cases annually?
Or that globally, the # of new cases will almost double by 2050?
We are working hard to change this.
Find out more: lnkd.in/ejqpUiZF
@britishlivertrust.bsky.social #OctoberIs4Livers
DYK: In the 🇬🇧 #liver #cancer has surged with over 6k new cases annually?
Or that globally, the # of new cases will almost double by 2050?
We are working hard to change this.
Find out more: lnkd.in/ejqpUiZF
@britishlivertrust.bsky.social #OctoberIs4Livers
October 1, 2025 at 9:57 AM
October is #LiverCancerAwarenessMonth.
DYK: In the 🇬🇧 #liver #cancer has surged with over 6k new cases annually?
Or that globally, the # of new cases will almost double by 2050?
We are working hard to change this.
Find out more: lnkd.in/ejqpUiZF
@britishlivertrust.bsky.social #OctoberIs4Livers
DYK: In the 🇬🇧 #liver #cancer has surged with over 6k new cases annually?
Or that globally, the # of new cases will almost double by 2050?
We are working hard to change this.
Find out more: lnkd.in/ejqpUiZF
@britishlivertrust.bsky.social #OctoberIs4Livers
The people affected by health innovations should have a voice in shaping them. That's why our PPRG sits at the heart of everything we do.
Hear from our members about why they got involved and the value they bring.
Interested in joining? Learn more: predictivehealthintelligence.co.uk/contact/
Hear from our members about why they got involved and the value they bring.
Interested in joining? Learn more: predictivehealthintelligence.co.uk/contact/
September 23, 2025 at 8:48 AM
The people affected by health innovations should have a voice in shaping them. That's why our PPRG sits at the heart of everything we do.
Hear from our members about why they got involved and the value they bring.
Interested in joining? Learn more: predictivehealthintelligence.co.uk/contact/
Hear from our members about why they got involved and the value they bring.
Interested in joining? Learn more: predictivehealthintelligence.co.uk/contact/
We're heading to #BASL2025!
Book a meeting with us to learn how we're ending the late diagnosis of #liverdisease: lnkd.in/ekvVUqP3
📍BASL 2025
🗺️ Belfast ICC
🗓️ 8 -10 October
#PublicHealth #CaseFinding #EarlyDiagnosis
Book a meeting with us to learn how we're ending the late diagnosis of #liverdisease: lnkd.in/ekvVUqP3
📍BASL 2025
🗺️ Belfast ICC
🗓️ 8 -10 October
#PublicHealth #CaseFinding #EarlyDiagnosis
September 18, 2025 at 8:54 AM
We're heading to #BASL2025!
Book a meeting with us to learn how we're ending the late diagnosis of #liverdisease: lnkd.in/ekvVUqP3
📍BASL 2025
🗺️ Belfast ICC
🗓️ 8 -10 October
#PublicHealth #CaseFinding #EarlyDiagnosis
Book a meeting with us to learn how we're ending the late diagnosis of #liverdisease: lnkd.in/ekvVUqP3
📍BASL 2025
🗺️ Belfast ICC
🗓️ 8 -10 October
#PublicHealth #CaseFinding #EarlyDiagnosis
Too many liver trials recruit from the same clinics, excluding those most affected. Our latest article looks at how broader eligibility, non-invasive tests, outreach, + case-finding can make research more representative.
www.linkedin.com/pulse/proble...
#LiverDisease #ClinicalTrials #HealthEquity
www.linkedin.com/pulse/proble...
#LiverDisease #ClinicalTrials #HealthEquity
The problem with liver trial bias, and how smart design can improve access.
Every new therapy relies on years of painstaking research, but what if that research overlooks the very people most in need? The problem: a mismatch between trials and reality Ethnic minorities, peopl...
www.linkedin.com
September 16, 2025 at 10:15 AM
Too many liver trials recruit from the same clinics, excluding those most affected. Our latest article looks at how broader eligibility, non-invasive tests, outreach, + case-finding can make research more representative.
www.linkedin.com/pulse/proble...
#LiverDisease #ClinicalTrials #HealthEquity
www.linkedin.com/pulse/proble...
#LiverDisease #ClinicalTrials #HealthEquity
Today we're launching “In practice with Dr Denver,” our new clinical insights series.
Read our first article about Alpha-1 Antitrypsin Deficiency, care gaps, and case-finding: www.linkedin.com/pulse/practi...
#LiverDisease #MedTech #A1ATD
Read our first article about Alpha-1 Antitrypsin Deficiency, care gaps, and case-finding: www.linkedin.com/pulse/practi...
#LiverDisease #MedTech #A1ATD
In Practice with Dr. Denver: How can case-finding help close care gaps for people with Alpha-1 Antitrypsin Deficiency (A1ATD)?
Care gaps are present across the care pathway for A1ATD-related liver disease; it is significantly underdiagnosed, suffers from a lack of awareness, and currently there are no approved pharmacological...
www.linkedin.com
September 9, 2025 at 7:51 AM
Today we're launching “In practice with Dr Denver,” our new clinical insights series.
Read our first article about Alpha-1 Antitrypsin Deficiency, care gaps, and case-finding: www.linkedin.com/pulse/practi...
#LiverDisease #MedTech #A1ATD
Read our first article about Alpha-1 Antitrypsin Deficiency, care gaps, and case-finding: www.linkedin.com/pulse/practi...
#LiverDisease #MedTech #A1ATD
Around 80% of liver disease cases in the UK are diagnosed too late, increasing pressure on secondary care.
Innovation is key to earlier diagnosis and efficient use of NHS resources.
See how we're making an impact: predictivehealthintelligence.co.uk/professional...
#LiverDisease #EarlyDiagnosis
Innovation is key to earlier diagnosis and efficient use of NHS resources.
See how we're making an impact: predictivehealthintelligence.co.uk/professional...
#LiverDisease #EarlyDiagnosis
August 21, 2025 at 8:31 AM
Around 80% of liver disease cases in the UK are diagnosed too late, increasing pressure on secondary care.
Innovation is key to earlier diagnosis and efficient use of NHS resources.
See how we're making an impact: predictivehealthintelligence.co.uk/professional...
#LiverDisease #EarlyDiagnosis
Innovation is key to earlier diagnosis and efficient use of NHS resources.
See how we're making an impact: predictivehealthintelligence.co.uk/professional...
#LiverDisease #EarlyDiagnosis
Addressing #SDoH is critical for equitable clinical trial access.
hepatoSIGHT™ helps identify underserved communities using deprivation indices, supporting inclusive recruitment.
Let’s ensure trials reflect the populations they aim to serve.
#LiverDisease #ClinicalTrials #HealthEquity
hepatoSIGHT™ helps identify underserved communities using deprivation indices, supporting inclusive recruitment.
Let’s ensure trials reflect the populations they aim to serve.
#LiverDisease #ClinicalTrials #HealthEquity
August 19, 2025 at 8:32 AM
Addressing #SDoH is critical for equitable clinical trial access.
hepatoSIGHT™ helps identify underserved communities using deprivation indices, supporting inclusive recruitment.
Let’s ensure trials reflect the populations they aim to serve.
#LiverDisease #ClinicalTrials #HealthEquity
hepatoSIGHT™ helps identify underserved communities using deprivation indices, supporting inclusive recruitment.
Let’s ensure trials reflect the populations they aim to serve.
#LiverDisease #ClinicalTrials #HealthEquity